Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: May 24, 2018

Right-To-Try Does Not Change Drug Company-Patient Interactions for Test Drugs

April 17, 2025May 24, 2018 by Prahsant Kumar

Right-To-Try is all set to become the law and the only big change is the shift in the role of FDA from an approver to observer for compassionate use of investigational products. The impact on patient access is limited at best and it does help the drug companies who own such investigational products but eliminating … Read more

Categories Blog

Impossible Burger Shows How Impossible FDA’s Job Is When It Comes to Food

April 17, 2025May 24, 2018 by Prahsant Kumar

One of FDA’s key roles in regulating food is to determine if the ingredients used are GRAS (Generally Recognized As Safe). It also requires food manufacturers to seek approval for using new dietary ingredients (NDI). Although FDA also regulates other aspects of food, such as quality, food manufacturers do not need preapproval from FDA before … Read more

Categories Blog

Recent Posts

  • From In silico to In vivo: Orchestrating AI for Breakthrough Therapeutics
  • Navigating the Hallucination Risks of Regulatory AI
  • Beyond the P-Value: Navigating the FDA’s New Bayesian Guidance for Drugs and Biologics
  • The Lean IND: Operationalizing the “Least Burdensome” Mandate
  • Beyond the LAL: Critical Updates to Bacterial Endotoxins and Pyrogen Testing

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.